Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.31 USD | -0.18% | -4.33% | +16.56% |
May. 31 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
May. 31 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.56% | 2.02B | |
-4.52% | 12.39B | |
-3.76% | 8.43B | |
+6.71% | 5.77B | |
+31.48% | 5.76B | |
-10.28% | 4.1B | |
+10.72% | 2.66B | |
-61.53% | 2.66B | |
-8.27% | 2.39B | |
-7.29% | 1.77B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Goldman Sachs Upgrades Myriad Genetics to Buy From Sell, Raises Price Target to $25 From $18